Disease Modifying Therapy for DMD: Utrophin Modulation Programme
|
|
- Dorthy Jenkins
- 7 years ago
- Views:
Transcription
1 Disease Modifying Therapy for DMD: Utrophin Modulation Programme PPMD Connect, June 2014
2 Legal Disclaimer FORWARD-LOOKING STATEMENTS This Document contains forward-looking statements. These statements relate to, among other things, analysis and other information that are based on forecasts of future results and estimates of amounts not yet determinable. These statements also relate to the Company s future prospects, developments and business strategies. Forward-looking statements are identified by their use of terms and phrases such as believe, could, envisage, estimate, expect, intend, may, plan, will or the negative of those, variations or comparable expressions, including references to assumptions. The forwardlooking statements in this Document are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. Given the risks and uncertainties associated with a company of this nature, potential investors should not place reliance on forward-looking statements. These forward-looking statements speak only as at the date of this Document. The Company does not undertake any obligation to update forward-looking statements or risk factors other than as required by any relevant regulations, whether as a result of new information, future events or otherwise. 2 PPMD Connect June 2014
3 Dystrophin or Utrophin Protein: Maintaining Integrity of Muscle Fibres Muscle fiber membrane Extracellular matrix Actin cytoskeleton Dystrophin or Utrophin Dystrophin or utrophin protein 3 PPMD Connect June 2014
4 Utrophin Modulation: A Disease-Modifying Approach for DMD Utrophin is functionally equivalent to dystrophin in both fetal and repairing muscle Utrophin is continually expressed at specialized sites in normal mature muscle fibers Normal Fiber Fetal (repairining) Time to Develop Fetal/ Immature Mature Utrophin modulation is a diseasemodifying strategy of potential utility for all DMD patients (independent of dystrophin mutation) DMD Fiber Degeneration Only normal utrophin levels required for DMD muscle recovery SMT C1100 designed to increase and maintain utrophin transcription DMD + SMT C1100 Fiber utrophin dystrophin 4 PPMD Connect June 2014
5 SMT C1100 Increased Utrophin Levels in Muscle Fibers Improves Disease Biomarkers In Vivo Reduced Fiber Regeneration (%CNFs) extensor digitorum longus tibialis anterior Reduced Muscle Leakiness (blood CK levels) mdx mdx + SMT C1100 Increased utrophin at the sarcolemma significantly reduces secondary disease effects 28 days of oral dosing (50mk/kg, QD) in mdx mice (n=5) Source: PLoS ONE, Vol 6, Issue 4, May 2011 mdx vehicle mdx+smt C PPMD Connect June 2014
6 UTROPHIN MODULATION PROGRAMME Clinical Data 6 PPMD Connect June 2014
7 Summary of Phase 1 Healthy Volunteer Trial Repeat dose Phase 1 healthy volunteer trial conducted in 2012 showed SMT C1100 was safe and well tolerated at all doses tested Achieved levels expected to increase utrophin expression for at least 14 hours/day Higher plasma levels achieved when SMT C1100 taken with food SMT C1100 taken with food v SMT C1100 taken after 12h fasting (same individuals after washout) 200mg/kg 7 PPMD Connect June 2014
8 Phase 1b Trial: Overview UK-based study 4 sites: London, Liverpool, Birmingham, Manchester 12 ambulatory DMD patients aged 5 to 11 years old 3 escalating dose cohorts, 4 patients per cohort: 50mg/kg BID, 100mg/kg BID, 100mg/kg TID 10 days of oral dosing Dosing to occur ideally within 10 minutes of consuming food Primary endpoint: Tolerability & Safety Secondary endpoint: PK levels of SMT C1100 and metabolites 8 PPMD Connect June 2014
9 Phase 1b Trial: Safety and PK First ever utrophin modulator trial in patients Safety: Primary endpoint of trial achieved SMT C1100 safe and well-tolerated in patients at all doses tested No apparent issues with patient compliance Variable Plasma levels of drug 2/12 boys had good SMT C1100 plasma levels appropriate for activating utrophin modulation 10/12 boys plasma levels were similar to fasted healthy adult volunteers 9 PPMD Connect June 2014
10 Phase 1b Trial: CK Observation Reduction in enzyme related to muscle damage Serum creatine kinase (CK) is an enzyme associated with muscle fibre damage and serum levels are elevated in DMD patients Reduced serum CK levels seen in non-clinical efficacy studies in mdx model after 15 days treatment with SMT C1100 Phase 1b data CK levels were reduced during dosing in the majority of boys Result is consistent with mdx data Consistent with reduction in muscle membrane damage 10 PPMD Connect June 2014
11 Next Steps: Targeting all Patients with DMD Future clinical trials of SMT C1100 to be modified to reflect our greater understanding of the importance of diet and other potential disease related factors Will seek to determine the optimal way to address drug exposure variability Dietary means and/or Drug formulation change Formulations already identified that increase exposure in animal studies Next patient study now expected to start in Q PPMD Connect June 2014
12 12 PPMD Connect June 2014
13 13 PPMD Connect June 2014
14 Alliance represents a multi-year strategic collaboration that combines extensive utrophin biology, chemistry and drug discovery expertise Commitment to build on the results obtained with SMT C1100 Aim to deliver first in-class and best in-class utrophin modulators for the therapy of DMD 14 PPMD Connect June 2014
15 Utrophin Modulation Programme Lead: SMT C1100 SMT C1100 related Next Generation DISCOVERY OPTIMISATION PRECLINICAL PHASE 1 PHASE 2 15 PPMD Connect June 2014
16 UTROPHIN MODULATION PROGRAMME Next Generation and Biomarkers 16 PPMD Connect June 2014
17 Next Generation Utrophin Modulators 1. Structurally Related to SMT C1100 Similar in vitro potency to SMT C1100, enhanced PK properties Clean safety/off target profile Rat In vivo PK Study 2. New structures, new mechanism New screening technology identifying differentiated utrophin modulators Potential new mechanism of action Increased in vitro activity compared to SMT C1100 Utrophin Levels in DMD patient Myoblasts 17 PPMD Connect June 2014
18 Biomarker Development Programme Utrophin / Mechanism Related UTRN localisation by quantitative IF UTRN mrna by QPCR UTRN protein by MS/MS Muscle Health From Muscle: Regeneration markers Inflammatory markers From Sera: Membrane damage (muscle enzymes, MicroRNAs) Active fibrosis (collagen fragments) Non-invasive Markers Muscle MRI 18 PPMD Connect June 2014
19 Thank You to the Community 19 PPMD Connect June 2014
20 Contact If you have further questions, do get in contact: Phone: +44 (0) Web: 20 PPMD Connect June 2014
GT-020 Phase 1 Clinical Trial: Results of Second Cohort
GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in
More informationDIAGNOSING CHILDHOOD MUSCULAR DYSTROPHIES
DIAGNOSING CHILDHOOD MUSCULAR DYSTROPHIES Extracts from a review article by KN North and KJ Jones: Recent advances in diagnosis of the childhood muscular dystrophies Journal of Paediatrics and Child Health
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationMuscular dystrophy clinical manifestations: progressive proximal extremity weakness respiratory muscle weakness cardiomyopathy
Muscular dystrophy clinical manifestations: progressive proximal extremity weakness respiratory muscle weakness cardiomyopathy Muscular dystrophy pathology: muscle fiber degeneration and regeneration Muscular
More informationMuscular dystrophy: basic facts
Muscular dystrophy: basic facts - heterogenous group of inherited disorders characterized by progressive muscle weakness and wasting (regeneration of muscle tissue fails) - most apparent or symptomatic
More informationBiological importance of metabolites. Safety and efficacy aspects
Biological importance of metabolites Safety and efficacy aspects Bernard Walther Technologie Servier Biological importance of metabolites Safety testing of drug metabolites Bioanalytical strategy Structural
More informationMuscular Dystrophy: Stem Cell Therapy
by Caitlin Pederson Abstract: Genetic disorders affect many people, and muscular dystrophy is a disorder that can greatly decrease the quality of life. Finding treatment to stop or prevent the loss of
More information2nd MuscleTech Network Workshop. From translational Research to translational Medicine. CONCLUSIONS AND CLOSING REMARKS Dr.
2nd MuscleTech Network Workshop. From translational Research to translational Medicine. CONCLUSIONS AND CLOSING REMARKS Dr. Carles Pedret MUSCLE AND TENDON WORKSHOP HEALTH AND GENERAL POPULATION SPORTS
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationHUNTINGTON S DISEASE THERAPIES RESEARCH UPDATE
HUNTINGTON S DISEASE MULTIDISCIPLINARY CLINIC HUNTINGTON S DISEASE THERAPIES RESEARCH UPDATE From gene to treatments The gene that causes Huntington s disease (HD) was discovered in 1993. Since then, enormous
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL
More informationReflection paper on clinical aspects related to tissue engineered products
1 2 3 19 March 2012 EMA/CAT/CPWP/573420/2009 Committee for Advanced Therapies (CAT) 4 5 6 Reflection paper on clinical aspects related to tissue engineered products Draft Draft agreed by CPWP 7 October
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationSession 6 Clinical Trial Assessment Phase I Clinical Trial
L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationSerum Creatine Kinase analysis in mouse models of muscular dystrophy.
Please quote this SOP in your Methods. Serum Creatine Kinase analysis in mouse models of muscular dystrophy. SOP (ID) Number MD_M.2.2.001 Version 2.0 Issued October 18th, 2008 Last reviewed March 25th,
More informationMedical Therapies Limited EGM Presentation
Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for
More informationStatistics and Pharmacokinetics in Clinical Pharmacology Studies
Paper ST03 Statistics and Pharmacokinetics in Clinical Pharmacology Studies ABSTRACT Amy Newlands, GlaxoSmithKline, Greenford UK The aim of this presentation is to show how we use statistics and pharmacokinetics
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationNewsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective:
Newsletter This resume of the results from the phase 1 study with Foxy-5 is based on clinical and laboratory data from the study, and these data have now been locked into the database. The full report
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page Sponsor Novartis Generic Drug Name BGT6 Therapeutic Area of Trial Advanced solid malignancies Approved Indication Investigational Study Number CBGT6A0 Title A phase
More informationFexinidazole a new oral treatment for sleeping sickness update of development
Fexinidazole a new oral treatment for sleeping sickness update of development SMe O 2 Me CH 2 O Antoine TARRAL Olaf Valverde Séverine Blesson Clélia Bardonneau Wilfried Mutumbo September 2011 Fexinidazole
More informationJAK1 and beyond. Investor Presentation February 2013. Copyright 2013 Galapagos NV
JAK1 and beyond Investor Presentation February 2013 Copyright 2013 Galapagos NV Disclaimer This presentation has been prepared by Galapagos and is furnished to you by Galapagos solely for your information.
More informationNon-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
More informationAchieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
More informationWeek 12 study results
Week 12 study results 15 April 2015 Copyright 2015 Galapagos NV Disclaimer This document may contain certain statements, including forward-looking statements, such as statements concerning the safety and
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationA Phase 2 Study of HTX-011 in the Management of Post-Operative Pain Positive Top-Line Results
A Phase 2 Study of HTX-011 in the Management of Post-Operative Pain Positive Top-Line Results September 22, 2015 Forward-Looking Statements This presentation contains "forward-looking statements" as defined
More informationTGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben?
TGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben? PD Dr. med. Thomas Sudhop Bundesinstitut für Arzneimittel, Bonn Bundesinstitut für Arzneimittel IMP
More informationLilly Covance Strategic Alliance From Vision to Results. Adrienne Takacs, PhD Jonathan Koch, MBA
Lilly Covance Strategic Alliance From Vision to Results Adrienne Takacs, PhD Jonathan Koch, MBA Topics 1. Lilly s Challenge... a Partnership Opportunity 2. Our Landmark Agreement 3. A Local Success Story
More informationProof-of-Concept Studies and the End of Phase IIa Meeting with the FDA
Medpace Discovery Series presents Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA DR. JIM WEI: Today my topic is going to be Proof-of-Concept Studies and FDA End of Phase 2a Meetings
More informationLead optimization services
Lead optimization services The WIL Research Company (WRC) has extensive experience in fast track tailor-made screening strategies to help you with the challenging task of selecting your best candidate
More informationLocalised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment
Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The
More informationGene Silencing Oligos (GSOs) Third Generation Antisense
Gene Silencing Oligos (GSOs) Third Generation Antisense Walter R. Strapps, Ph.D. Executive Director, RNA Therapeutics Idera Pharmaceuticals Cambridge, MA NASDAQ: IDRA www.iderapharma.com Idera is a leader
More informationThe Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
More informationA Peak at PK An Introduction to Pharmacokinetics
Paper IS05 A Peak at PK An Introduction to Pharmacokinetics Hannah Twitchett, Roche Products Ltd, Welwyn Garden City, UK Paul Grimsey, Roche Products Ltd, Welwyn Garden City, UK ABSTRACT The aim of this
More informationCompany Update. March 2011
Company Update March 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various
More informationGuidance for Industry
Guidance for Industry Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationNONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
More informationBNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
More informationSummary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor)
EMA/662624/2015 Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) This is a summary of the risk management plan (RMP) for Orkambi, which details the measures to be taken
More informationFSH Society s 2014 Biennial FSHD Connect Meeting: Natural History Studies
FSH Society s 2014 Biennial FSHD Connect Meeting: Natural History Studies Raymond A. Huml, MS, DVM, RAC Executive Director, Head, Global Biosimilars Business Development and Strategic Planning, Quintiles
More informationJAK1 and beyond. Investor Presentation January 2014. Copyright 2014 Galapagos NV
JAK1 and beyond Investor Presentation January 2014 Copyright 2014 Galapagos NV Disclaimer This presentation has been prepared by Galapagos and is furnished to you by Galapagos solely for your information.
More informationCAN-FITE BIOPHARMA LTD.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationSheffield Kidney Institute. Planning a Clinical Trial
Planning a Clinical Trial Clinical Trials Testing a new drug Ethical Issues Liability and Indemnity Trial Design Trial Protocol Statistical analysis Clinical Trials Phase I: Phase II: Phase III: Phase
More informationQ4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO
Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO 1 PCI BIOTECH Important notice and disclaimer This presentation may contain certain forward-looking statements and forecasts based
More informationDec. 9, 2013, 11:00 a.m. EST
Dec. 9, 2013, 11:00 a.m. EST Portola Pharmaceuticals Announces New Phase 2 Results Confirming Immediate, Dose-Dependent and Well-Tolerated Reversal of Anticoagulation Activity of XARELTO(R) (rivaroxaban)
More informationGalapagos reports largest cash balance ever
Regulated information 3 March 2016, 22.00 CET Galapagos reports largest cash balance ever Key 2015 financials: Cash burn of 122 million, in line with guidance Cash balance on 31 December 2015 of 348 million
More informationRare Diseases: Common Issues in Drug Development Guidance for Industry
Rare Diseases: Common Issues in Drug Development Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
More informationDelivering gene therapy to patients
Delivering gene therapy to patients FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements
More informationChapter 10. Summary & Future perspectives
Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral
More informationGENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 Current
More informationDeveloping Innovative Therapeutics for People with Orphan Liver Disease
Developing Innovative Therapeutics for People with Orphan Liver Disease PIPELINE PROGRESS AND FIRST QUARTER 2015 EARNINGS UPDATE NASDAQ: OCRX Forward-Looking Statements Certain statements in this presentation
More informationVITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS
39 Chapter 3 VITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS Maxine Briggs TABLE OF CONTENTS I. Review of the
More informationDuchenne muscular dystrophy
Duchenne muscular dystrophy Penny Southall, mum of Dan Hanson: My son, Dan, was diagnosed with Duchenne muscular dystrophy when he was three years old. I know the diagnosis can be devastating. Like we
More informationPARP inhibitors and TEMOZOLAMIDE in BRAIN TUMORS. Idoia Morilla Ruiz
PARP inhibitors and TEMOZOLAMIDE in BRAIN TUMORS Idoia Morilla Ruiz DNA REPAIR SYSTEM Cancer Sci 105 ( 2014) 370-388 Until recently, treatment efforts have focussed on maximizing the DNA damage (limited
More informationM4E(R2): The CTD Efficacy
M4E(R2): The CTD Efficacy This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationTeriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).
Page 1 of 10 ANALYTE NAME AND STRUCTURE TERIFLUNOMIDE Teriflunomide TRADE NAME Aubagio CATEGORY Antimetabolite TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND sclerosis. The
More informationGuidance for Industry
Guidance for Industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
More informationEffets biologiques des facteurs de croissance sur la régénération musculaire
Effets biologiques des facteurs de croissance sur la régénération musculaire Xavier Bigard (MD, PhD) Professeur Agrégé du Val-de-Grâce Institut de Recherche Biomédicale des Armées (IRBA) La Tronche (Grenoble)
More informationMATHEMATICAL MODELS OF TUMOR GROWTH INHIBITION IN XENOGRAFT MICE AFTER ADMINISTRATION OF ANTICANCER AGENTS GIVEN IN COMBINATION
MATHEMATICAL MODELS OF TUMOR GROWTH INHIBITION IN XENOGRAFT MICE AFTER ADMINISTRATION OF ANTICANCER AGENTS GIVEN IN COMBINATION Nadia Terranova UNIVERSITÀ DI PAVIA New model development: course of action
More informationICH Topic E 8 General Considerations for Clinical Trials. Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95)
European Medicines Agency March 1998 CPMP/ICH/291/95 ICH Topic E 8 General Considerations for Clinical Trials Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95) TRANSMISSION
More informationHow To Get A Grant From Kinesis
- The collaboration initiative to move drug candidates forward Introduction What are we offering? How? Why apply? Terms Background For grant applications and to attract venture capital start-up companies
More informationEVT Execute & EVT Innovate Leading drug discovery
EVT Execute & EVT Innovate Leading drug discovery Evotec AG, Nine-month 2015 Interim Report, 10 November 2015 Forward-looking statements Information set forth in this presentation contains forward-looking
More informationEffective Outsourcing of Clinical Pharmacology Studies in Europe. John Horkulak Executive Director, Eurasian External Clinical Study Operations
Effective Outsourcing of Clinical Pharmacology Studies in Europe John Horkulak Executive Director, Eurasian External Clinical Study Operations Key Questions Do clinical pharmacology studies require a different
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationFACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN
FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company
More informationClinical Trials and YOU
Clinical Trials and YOU What are clinical trials? Controlled studies to determine how a particular anti-cancer strategy ( i.e. treatment ) affects the people who receive it Involve rigorous scientific
More informationStem Cell-based Therapies and FDA Regulations
Stem Cell-based Therapies and FDA Regulations By Trina Slabiak, MS, RAC Stem cell-based therapies are arriving in the clinic as Phase 1 studies. Which technological challenges and US Food and Drug Administration
More informationSanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)
PRESS RELEASE Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL) Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases
More informationCorporate Booklet February 2016
Corporate Booklet February 2016 Certain statements contained herein including, but not limited to, expected licensing transactions, statements related to anticipated timing of initiation and completion
More informationRisk Assessment in Chemical Food Safety. Dept. of Food Safety and Zoonoses (FOS) http://www.who.int/foodsafety/en/
Risk Assessment in Chemical Food Safety Dept. of Food Safety and Zoonoses (FOS) http://www.who.int/foodsafety/en/ Risk Analysis Paradigm Internationally Scientific data analysis Risk Assessment WHO & FAO
More informationAbbott Nutrition. Attractive Profile and Compelling Growth Opportunities
Attractive Profile and Compelling Growth Opportunities Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation
More informationMultiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report
Multiple Sclerosis in Practice An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Clinical Context: Multiple Sclerosis in Practice Expert Commentary Jointly Sponsored by: and Clinical
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationWntResearch. Foxy-5 A unique Phase 1 opportunity to combat the spreading of cancer
WntResearch Foxy-5 A unique Phase 1 opportunity to combat the spreading of cancer Why WntResearch is developing novel anti-cancer drugs Approximately 55 000 Swedish citizens are diagnosed with cancer every
More informationFirst In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases Andrew E. Mulberg, MD, FAAP Division Deputy Director OND/ODE3/DGIEP FDA Partnership is the Key Coming together is a beginning;
More informationLeveraging Biomarkers in Early Clinical Drug Development for Metabolic Disease Therapies. Mallé Jurima-Romet, PhD August 31, 2011
Leveraging Biomarkers in Early Clinical Drug Development for Metabolic Disease Therapies Mallé Jurima-Romet, PhD August 31, 2011 Overview of Presentation What is driving the need for innovation in early
More informationBAY 1187982, a novel ADC with potent anti-tumor activity, targeting all isoforms of FGFR2
BAY 1187982, a novel ADC with potent anti-tumor activity, targeting all isoforms of FGFR2 6 th World ADC, San Diego, October 20, 2015 Anette Sommer Disclosure Information I have the following financial
More informationNew Advances in Cancer Treatments. March 2015
New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within
More informationCareers in Biostatistics and Clinical SAS Programming An Overview for the Uninitiated Justina M. Flavin, Independent Consultant, San Diego, CA
PharmaSUG 2014 Paper CP07 Careers in Biostatistics and Clinical SAS Programming An Overview for the Uninitiated Justina M. Flavin, Independent Consultant, San Diego, CA ABSTRACT In the biopharmaceutical
More informationa Phase 2 prostate cancer clinical trial is ongoing. Table 2: Squalamine vs Standard-of-care literature
PRODUCT FACT SHEET Spring 2007 MISSION STATEMENT Genaera Corporation is a biopharmaceutical company with a focus on metabolic and respiratory diseases. The compounds in the Genaera pipeline address signal
More informationALPHA (TNFa) IN OBESITY
THE ROLE OF TUMOUR NECROSIS FACTOR ALPHA (TNFa) IN OBESITY Alison Mary Morris, B.Sc (Hons) A thesis submitted to Adelaide University for the degree of Doctor of Philosophy Department of Physiology Adelaide
More informationEuropean Medicines Agency decision
EMA/792653/2014 European Medicines Agency decision P/0025/2015 of 30 January 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationMuscle Physiology and the. Pathology of Muscular Dystrophy
Muscle Physiology and the Pathology of Muscular Dystrophy Angela Tompkins February 23, 2010 Everglades University Biology 1 Muscle Physiology and the Pathology of Muscular Dystrophy Humans are able to
More informationGuidance for Industry
Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
More informationTranslation of Regenerative Medicine. Prof Trevor M Jones CBE
Translation of Regenerative Medicine Prof Trevor M Jones CBE ReNeuronre UK s only clinical stage stem cell therapy Company Established 1997 - King s College London (IOP) Based in Guildford, Surrey Focused
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
More informationBasic Overview of Preclinical Toxicology Animal Models
Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background
More informationGuidance for Industry Safety Testing of Drug Metabolites
Guidance for Industry Safety Testing of Drug Metabolites U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2008 Pharmacology
More informationGuidance for Industry
Guidance for Industry Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs General Considerations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationGUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
More information5 Frequently Asked Questions About Adult Stem Cell Research
5 Frequently Asked Questions About Adult Stem Cell Research Stem cells are often referred to in the sociopolitical realm with some level of controversy and beyond that, some level of confusion. Many researchers
More informationICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
More informationVERTEX PHARMACEUTICALS INC / MA
VERTEX PHARMACEUTICALS INC / MA FORM 8-K (Unscheduled Material Events) Filed 6/1/2005 For Period Ending 5/31/2005 Address 130 WAVERLY STREET CAMBRIDGE, Massachusetts 02139-4242 Telephone 616-577-6000 CIK
More informationLongitudinal Modeling of Lung Function in Respiratory Drug Development
Longitudinal Modeling of Lung Function in Respiratory Drug Development Fredrik Öhrn, PhD Senior Clinical Pharmacometrician Quantitative Clinical Pharmacology AstraZeneca R&D Mölndal, Sweden Outline A brief
More informationFreiburg Study. The other 24 subjects had healthy markers closer to what would be considered ideal.
Freiburg Study The Freiburg Study was conducted with 48 healthy human subjects of various ages. None of the test subjects had been diagnosed with any disease prior to the study. None were taking any type
More information